Accession Therapeutics Limited
Samantha Moore has worked as a Scientist at Accession Therapeutics Limited starting in November 2021. Prior to that, they were a Postdoctoral Research Associate at the University of Oxford from January 2020 to November 2020. Samantha also has experience as a Research Technician at Ludwig Cancer Research from October 2014 to October 2015, and completed an internship at Adaptimmune in July 2012.
Samantha Moore attended Matthew Arnold School in Oxford from 2004 to 2011. However, no information about a degree or field of study is available for this period.
After completing their secondary education, Samantha pursued higher education at the University of Oxford. From 2011 to 2014, they earned a Bachelor of Arts (BA) degree in Biology/Biological Sciences with a focus on general topics.
Following their undergraduate studies, Samantha continued their academic journey at the University of Oxford. From 2015 to 2020, they pursued a Doctor of Philosophy (PhD) in Clinical Medicine.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.